PRESSRELEASES

13 October, 2021

Nanexa signs additional evaluation agreement

Nanexa AB today announced that the company has signed an additional so-called Material Transfer and Feasibility Study Agreement with one of the company’s existing customers, for evaluation of the PharmaShell® technology with a specific biological drug substance.

5 October, 2021

Nanexa receives decision on sanction fee from Finansinspektionen regarding case from 2017

Nanexa AB today announces that the company has received a decision from Finansinspektionen (Sweden’s financial supervisory authority) to pay a penalty fee of SEK 1,000,000 regarding events that occurred in 2017.

CURRENT

28 juni, 2021

Redeye analytiker-intervju med vd David Westberg



17 juni, 2021

Webcast och frågestund

NEWSLETTER

Meet Nanexa

  • No scheduled meetings